RT Journal Article
SR Electronic
T1 Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.12.21249577
DO 10.1101/2021.01.12.21249577
A1 Matthew L. Meizlish
A1 George Goshua
A1 Yiwen Liu
A1 Rebecca Fine
A1 Kejal Amin
A1 Eric Chang
A1 Nicholas DeFilippo
A1 Craig Keating
A1 Yuxin Liu
A1 Michael Mankbadi
A1 Dayna McManus
A1 Stephen Wang
A1 Christina Price
A1 Robert D. Bona
A1 Cassius Iyad Ochoa Chaar
A1 Hyung J. Chun
A1 Alexander B. Pine
A1 Henry M. Rinder
A1 Jonathan Siner
A1 Donna S. Neuberg
A1 Kent A. Owusu
A1 Alfred Ian Lee
YR 2021
UL http://medrxiv.org/content/early/2021/01/15/2021.01.12.21249577.abstract
AB Background Thrombotic complications occur at high rates in hospitalized patients with COVID-19, yet the impact of intensive antithrombotic therapy on mortality is uncertain.Research Question How does in-hospital mortality compare with intermediate-versus prophylactic-dose anticoagulation, and separately with in-hospital aspirin versus no antiplatelet therapy, in treatment of COVID-19?Study Design and Methods Using data from 2785 hospitalized adult COVID-19 patients, we established two separate, nested cohorts of patients (1) who received intermediate- or prophylactic-dose anticoagulation (“anticoagulation cohort”, N = 1624), or (2) who were not on home antiplatelet therapy and received either in-hospital aspirin or no antiplatelet therapy (“aspirin cohort”, N = 1956). Propensity score matching utilizing various markers of illness severity and other patient-specific covariates yielded treatment groups with well-balanced covariates in each cohort. The primary outcome was cumulative incidence of in-hospital death.Results Among propensity score-matched patients in the anticoagulation cohort (N = 382), in a multivariable regression model, intermediate-compared to prophylactic-dose anticoagulation was associated with a significantly lower cumulative incidence of in-hospital death (hazard ratio 0.518 [0.308-0.872]). Among propensity-score matched patients in the aspirin cohort (N = 638), in a multivariable regression model, in-hospital aspirin compared to no antiplatelet therapy was associated with a significantly lower cumulative incidence of in-hospital death (hazard ratio 0.522 [0.336-0.812]).Interpretation In this propensity score-matched, observational study of COVID-19, intermediate-dose anticoagulation and aspirin were each associated with a lower cumulative incidence of in-hospital death.Summary conflict of interest statements No conflict of interest exists for any author on this manuscript.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a gift donation from Jack Levin and a separate anonymous donation to the Benign Hematology program at Yale, the DeLuca Foundation to fund hematology research at Yale, and the National Institutes of Health (grant HL142818 to H.J.C., and GM136651 and HL139116 to M.L.M.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Yale Institutional Review Board (HIC 2000027792). An additional, approved Data Use Agreement between Yale and Dana-Farber Cancer Institute permitted analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll authors have access to the data provided in this manuscript.